Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2018; 8(19):5307-5319. doi:10.7150/thno.26823 This issue Cite

Review

EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers

Lijun Jiang1, Chen Xie1, Hong Lok Lung2, Kwok Wai Lo4✉, Ga-Lai Law3✉, Nai-Ki Mak2✉, Ka-Leung Wong1✉

1. Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China.
2. Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China.
3. Department of Applied Biological and Chemical Technology, Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China.
4. Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China.

✉ Corresponding authors: Email: klwongedu.hk; nkmakedu.hk; ga-ai.lawedu.hk; kwloedu.hk

Citation:
Jiang L, Xie C, Lung HL, Lo KW, Law GL, Mak NK, Wong KL. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics 2018; 8(19):5307-5319. doi:10.7150/thno.26823. https://www.thno.org/v08p5307.htm
Other styles

File import instruction

Abstract

Graphic abstract

Epstein-Barr virus (EBV) infects more than 90% of humans worldwide and establishes lifelong latent infection in the hosts. It is closely associated with endemic forms of a wide range of human cancers and directly contributes to the formation of some. Despite its critical role in cancer development, no EBV- or EBV latent protein-targeted therapy is available. The EBV-encoded latent protein, Epstein-Barr nuclear antigen 1 (EBNA1), is expressed in all EBV-associated tumors and acts as the only latent protein in some of these tumors. This versatile protein functions in the maintenance, replication, and segregation of the EBV genome and can therefore serve as an attractive therapeutic target to treat EBV-associated cancers. In the last decades, efforts have been made for designing specific EBNA1 inhibitors to decrease EBNA1 expression or interfere with EBNA1-dependent functions. In this review, we will briefly introduce the salient features of EBNA1, summarize its functional domains, and focus on the recent developments in the identification and design of EBNA1 inhibitors related to various EBNA1 domains as well as discuss their comparative merits.

Keywords: EBNA1-targeted inhibitor, fluorescent probe, EBV-associated cancers, EBV, EBNA1

Citation styles

APA
Jiang, L., Xie, C., Lung, H.L., Lo, K.W., Law, G.L., Mak, N.K., Wong, K.L. (2018). EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics, 8(19), 5307-5319. https://doi.org/10.7150/thno.26823.

ACS
Jiang, L.; Xie, C.; Lung, H.L.; Lo, K.W.; Law, G.L.; Mak, N.K.; Wong, K.L. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics 2018, 8 (19), 5307-5319. DOI: 10.7150/thno.26823.

NLM
Jiang L, Xie C, Lung HL, Lo KW, Law GL, Mak NK, Wong KL. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics 2018; 8(19):5307-5319. doi:10.7150/thno.26823. https://www.thno.org/v08p5307.htm

CSE
Jiang L, Xie C, Lung HL, Lo KW, Law GL, Mak NK, Wong KL. 2018. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 8(19):5307-5319.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use